Chemotherapy

Pharmacology

Histone H1 Modulates the Antioxidant Status in 9,10-Dimethylbenz[a]anthracene-Induced Experimental Breast Cancer

Vani G. · Shyamala Devi C.S.

Author affiliations

Department of Biochemistry, University of Madras, Guindy Campus, Chennai, India

Keywords: Antioxidant enzymesBreast cancerErythrocyte membraneFatty acidsHistone H1Oxidative stress

Related Articles for ""
Chemotherapy 2005;51:57–63
https://doi.org/10.1159/000085768

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Pharmacology

Received: July 15, 2004
Accepted: November 19, 2004
Published online: June 03, 2005
Issue release date: May 2005

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Abstract

Aim: Oxidative stress is implicated in the pathogenicity of cancer cells and contributes towards the response to antineoplastic agents. This study was aimed at assessing the antioxidant status in 9,10-dimethylbenz[a]anthracene-induced experimental animals treated with histone H1. Methods: Histone H1 was injected and the antioxidant status was assessed in erythrocytes and tumour tissue of experimental animals. The antioxidant status was monitored from the levels of lipid peroxides as thiobarbituric acid reactants and conjugated dienes in the haemolysate, serum, glutathione, and plasma vitamins A, E, C and ceruloplasmin. In the haemolysate, activities of antioxidant enzymes, including superoxide dismutase, catalase, glutathione reductase, γ-glutamyl transpeptidase, glutathione S-transferase, glutathione peroxidase and glucose-6-phosphate dehydrogenase, were assayed and erythrocyte fatty acid composition was analyzed by gas chromatography-mass spectrometry. All of the above parameters except fatty acid composition were assessed within the tumour tissue to assess the antioxidant status. Results: Treatment with histone H1 enhanced the antioxidant in erythrocyte at the end of the 2nd and 4th week by significantly decreasing thiobarbituric acid-reactive substances and conjugated dienes, by increasing glutathione levels, activities of antioxidant enzymes and favourably altering the erythrocyte fatty acid composition. Within the tumour tissue, a significant atrophy with significant alteration in antioxidant and antioxidant enzyme status was evident in treatment. Conclusion: These results validate the role of histone H1 as an antitumour agent in breast cancer.

© 2005 S. Karger AG, Basel



Related Articles:

References

  1. Class R, Lindman S, Fassbender C, Leinenbach HP, Rawer S, Emrich JG, Brady LW, Zeppezauer M: Histone H1 suppresses tumour growth of leukaemia cells in vitro, ex vivo and in an animal model suggesting extracellular functions of histones. Am J Clin Oncol 1996;19:522–531.
  2. Rakowicz-Szulczynska EM, McIntosh DG, Lewis P, Smith ML: Inhibition of cancer cell growth by internalized immuno-histone conjugates. Cancer Biother Radiopharm 1996;11:77–86.
  3. Konishi A, Shimizu S, Hirota J, Takao T, Fan Y, Matsuako Y, Zhang L, Yoneda Y, Fujii Y, Skoultchi AI, Tsujimoto Y: Involvement of histone H1.2in apoptosis induced by DNA double-strand breaks. Cell 2003;114:673–688.
  4. Kleine TJ, Gladfelter A, Lewis PN, Lewis SA: Histone-induced damage of a mammalian epithelium: The conductive effect. Am J Physiol 1995;268:C1114–C1125.
  5. Hiemstra PS, Eisenhauer PB, Harwig SSL, van den Barselaar MT, van Furth R, Lehrer RI: Antimicrobial proteins of murine macrophages. Infect Immun 1993;61:3038–3046.
  6. Konopinska D, Nawrocka E, Siemion IZ, Slopek S, Szymaniec ST, Klonowska E: Partial sequences of histones with tuftsin activity. Int J Pept Protein Res 1977;9:71–77.
  7. Reichhart R, Zeppezauer M, Jornvall H: Preparations of homeostatic thymus hormone consist predominantly of histones 2A and 2B and suggest additional histone functions. Proc Natl Acad Sci USA 1985;82:4871–4875.
  8. Zeppezauer M, Reichhart R: Use of histone H1 and H2A:H2B dimers in therapeutic methods. US Patent 1989;5:218–257.
  9. Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J 1996;313:17–29.
  10. Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794–798.
  11. Weijl NI, Cleton FJ, Osanto S: Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 1997;23:209–240.
  12. Fulton AM, Chong YC: The role of macrophage-derived TNFα in the induction of sublethal tumor cell DNA damage. Carcinogenesis 1992;13:77–81.
  13. O’Donnell-Tormey J, DeBoer CJ, Nathan CF: Resistance of human tumor cells in vitro to oxidative cytolysis. J Clin Invest 1985;76:80–86.
  14. Vani G, Devipriya S, Shyamaladevi CS: Histone H1 modulates the immune status in experimental breast cancer. Chemotherapy 2003;49:252–256.
  15. Van Kampen E, Ziljstra WG: Determination of hemoglobin and its derivatives; in Sobotka H, Stewart CP (eds.): Advances in Clinical Chemistry. New York, Academic Press, 1965, pp 425–522.
  16. Poli G, Dianazani M, Cheeseman KH, Slater TF, Lang J, Esterbauer H: Separation and characterization of the aldehydic products of lipid peroxidation stimulated by carbon tetrachloride or ADP-iron in isolated rat hepatocytes and rat liver microsomal suspensions. Biochem J 1985;227:629–638.
  17. Beswick PH, Cheeseman KH, Poli G, Slater TF: in Slater TF, Garner A (eds): Recent Advances in Lipid Peroxidation and Tissue Injury. Uxbridge, Brunel University Press, 1981, pp 156–176.
  18. Uchiyama M, Mihara M: Determination of malondialdehyde precursors in tissues by thiobarbituric acid test. Anal Biochem 1978;86:271–278.
  19. Klein RA: The detection of oxidation in liposome preparation. Biochim Biophys Acta 1970;210:486–489.
  20. Moron MS, Depierre JW, Mannervik B: Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 1979;582:67–78.
  21. Bessey OA, Lowry OH, Brock MJ, Lopez JA: The determination of vitamin A and carotene in small quantities of blood serum. J Biol Chem 1946;166:177–188.
  22. Gould BS, Shwachman H, Lenney JF: A new method for the bioassay of antiscorbutica substances. Assays of dehydroascorbic acid, 2-ketogulonic acid, iron ascorbate, and the effectiveness of oral and parenteral administration of ascorbic acid. J Biol Chem 1943;151:439–453.
  23. Iuliano L, Micheletta F, Natoli S, Ginanni Corradini S, Iappelli M, Elisei W, Giovannelli L, Violi F, Diczfalusy U: Measurement of oxysterols and alpha-tocopherol in plasma and tissue samples as indices of oxidant stress status. Anal Biochem 2003;312:217–223.
  24. Ravin HA: An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 1961;58:161–168.
  25. Misra HP, Fridovich I: The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;247:3170–3175.
  26. Beers R Jr, Sizer JW: Spectrophotometric method for measuring breakdown of H2O2 by catalase. J Biol Chem 1952;195:133–140.
  27. Jacobs WL: A colorimetric assay for gamma-glutamyl transpeptidase. Clin Chim Acta 1971;31:175–179.
  28. Rotruck JT, Pope AL, Ganther HE: Selenium: Biochemical role as a component of glutathione peroxidase, purification and assay. Science 1973;179:588–590.
  29. Habig WH, Pabst MJ, Lakoby WB: Glutathione S-transferase, the first enzymatic step in mercapturic acid formation. J Biol Chem 1974;249:7130–7139.
  30. Glock GE, McLean P: Further studies on the properties and assay of glucose 6-phosphate dehydrogenase of rat liver. Biochem J 1953;53:400–408.
  31. Alexander IS, Justice JB: Fatty acid composition of erythrocyte membrane by gas column mass spectrometry. J Chromatogr 1985;342:1–12.
  32. Lowry OH, Rosebrough NJ, Farr AL, Randall AJ: Protein measurement with Folins phenol reagent. J Biol Chem 1951;193:262–275.
  33. Batko J: The effect of experimental neoplastic disease on malondialdehyde level and glutathione status in erythrocytes of rats. Acta Biochim Pol 1997;44:767–769.
  34. Batko J, Warchol T, Karon H: The activities of superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase in erythrocytes of rats with experimental neoplastic disease. Acta Biochim Pol 1996;43:403–405.
  35. Navarro J, Obrador E, Carretero J, Petschen I, Avino J, Perez P, Estrela JM: Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med 1999;26:410–418.
  36. Subramaniam S, Subramaniam S, Jagadeesan M, Devi CS: Alterations in erythrocyte membrane structure of breast cancer patients treated with CMF – A lipid profile. Chemotherapy 1994;40:427–430.
  37. Vasigara Singh W, Subramaniam S, Shyama S, Jagadeesan M, Shyamala Devi CS: Changes in erythrocyte membrane lipids in breast cancer after radiotherapy and chemotherapy. Chemotherapy 1996;42:65–70.
  38. May JM, Qu ZC, Mendiratta S: Protection and recycling of alpha-tocopherol in human erythrocytes by intracellular ascorbic acid. Arch Biochem Biophys 1998;349:281–289.
  39. May JM, Qu ZC, Whitesell RR: Ascorbic acid recycling enhances the antioxidant reserve of human erythrocytes. Biochemistry 1995;34:12721–12728.
  40. Napoli JL, McCormick AM, O’Meara B, Dratz EA: Vitamin A metabolism: Alpha-tocopherol modulates tissue retinol levels in vivo, and retinyl palmitate hydrolysis in vitro. Arch Biochem Biophys 1984;230:194–202.
  41. Kanazawa K, Ashida H: Target enzymes on hepatic dysfunction caused by dietary products of lipid peroxidation. Arch Biochem Biophys 1991;288:71–78.
  42. Giannitsis DJ: Alcohols-histones metabolic interactions in intact human erythrocytes. Arzneimittelforschung 1977;27:1595–1597.
  43. Giannitsis DJ: Effect of histones on the intracellular metabolism of ascorbic acid. Arzneimittelforschung 1977;27:353–354.
  44. Giannitis DJ: Stimulatory effect of histone on glutathione reductase of human erythrocytes. Arzneimittelforschung 1978;28:300–301.
  45. Meister A: Glutathione, ascorbate and cellular protection. Cancer Res 1994;54(suppl):1969–1974.
  46. Vaidya SM, Kamalakar PL: Copper and ceruloplasmin levels in serum of women with breast cancer. Indian J Med Sci 1998;52:184–187.
  47. Coban T, Mabsout A, Eke BC, Bulbul D, Berberoglu U, Iscan M: Glutathione and lipid peroxidation levels in human breast tumors. Neoplasma 1998;45:151–156.
  48. Nikiforova NV, Berman AE: Antioxidants in malignant neoplasms in humans and animals. Biomed Khim 2003;49:250–262.
  49. Khanzode SS, Muddeshwar MG, Khanzode SD, Dakhale GN: Antioxidant enzymes and lipid peroxidation in different stages of breast cancer. Free Radic Res 2004;38:81–85.
  50. McEwen BS, Allfrey VG, Mirsky AE: Studies on the energy yielding reactions in thymus nuclei. 1. Comparison of nuclear and mitochondrial phosphorylation. J Biol Chem 1963;238:758–768.
  51. Allfrey VG, Littau VC, Mirsky AE: On the role of histones in regulating ribonucleic acid synthesis in the cell. Symp Quant Biol 1963;29:247–263.

Article / Publication Details

First-Page Preview
Abstract of Pharmacology

Received: July 15, 2004
Accepted: November 19, 2004
Published online: June 03, 2005
Issue release date: May 2005

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2005, Vol.51, No. 2-3

May 2005

Article

Recommend This
TOP